Ausgabe 1/2009
Inhalt (15 Artikel)
Inhibition of the RAS and prevention of diabetes and CVD: Mechanistic insights and lessons learned from clinical trials
Samy I. McFarlane, Jeffrey S. Borer
Clinical Trials Report
Preventing cardiovascular disease in type 2 diabetes: Where do things stand with glycemic control? Part one
Alan Chait
Clinical Trials Report
Preventing cardiovascular disease in type 2 diabetes: Where do things stand with glycemic control? Part two
Alan Chait
Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes
Michelle M. Averill, Karin E. Bornfeldt
Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia
Dario A. Gutierrez, Michael J. Puglisi, Alyssa H. Hasty
Clinical Trials Report
Weight loss and diets: Which diet works best?
Anders Carlson, Richard E. Pratley
Metabolic syndrome associated with HIV and highly active antiretroviral therapy
Giuseppe Barbaro, Gialuca Iacobellis
Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap
Roger S. McIntyre, Natalie L. Rasgon, David E. Kemp, Ha T. Nguyen, Candy W. Y. Law, Valerie H. Taylor, Hanna O. Woldeyohannes, Mohammad T. Alsuwaidan, Joanna K. Soczynska, Byungsu Kim, Maria T. Lourenco, Linda S. Kahn, Benjamin I. Goldstein
Clinical Trials Report
The “legacy effect” associated with intensive glucose control in patients with type 2 diabetes
Jayanta T. Mukherjee, Richard W. Nesto
Diabetes and cardiovascular disease: The role of glycemic control
Alice Y. Y. Cheng, Lawrence A. Leiter
Type 2 diabetes and coronary heart disease: Focus on myocardial infarction
Rodrigo M. Lago, Richard W. Nesto
The failing diabetic heart: Focus on diastolic left ventricular dysfunction
Loek van Heerebeek, Aernout Somsen, Walter J. Paulus